Eris Lifesciences eyes high-margin segments

In 2016, Eris acquired 75.48% in Kinedex, for an aggregate consideration of Rs 77.18 crore

Ahmedabad-based Eris Lifesciences has evolved as a sizeable player in its core offering — cardiovascular segment — within a decade, and is now eyeing growth in high-margin segments like dermatology, osteoarthritis and neurology, among others. 

True to its strategy of focussing on lifestyle segments, the company, which has been clocking a 21.7 per cent CAGR from FY13 to FY17, made its first acquisition after listing — UTH Healthcare. 

UTH, a nutraceuticals company, is largely engaged in segments of obesity, diabetes, gestational diabetes mellitus, maternal nutrition and cardio-vascular diseases, the areas Eris is particularly focusing on. 

A mail sent to Eris